ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary

Fuster, Valentín; Rydén, Lars; Cannom, David S.; Crijns, Harry J.G.M.; Curtis, Anne B.; Ellenbogen, Kenneth A.; Heuzey, Jean‐Yves Le; Kay, G. Neal; Lowe, James E.; Olsson, Sandra; Prystowsky, Eric N.; Wann, Samuel; Smith, Sidney C.; Jacobs, Alice K.; Adams, Cynthia D.; Anderson, J. Lawford; Antman, Elliott M.; Halperin, Jonathan L.; Hunt, Sharon A.; Nishimura, Rick A.; Ornato, Joseph P.; Page, Richard L.; Riegel, Bárbara; Priori, Silvia G.; Blanc, Jean‐Jacques; Budaj, Andrzej; Camm, A. John; Dean, Veronica; Deckers, Jaap W.; Despres, Catherine; Dickstein, Kenneth; Lekakis, John; McGregor, Keith; Metra, Marco; Morais, João; Osterspey, A.; Tamargo, Juan; Zamorano, José Luís

doi:10.1161/circulationaha.106.177031

Cited by 264 publications

(43 citation statements)

References 418 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At that time, evidence-based practice guidelines recommended long-term antithrombotic therapy with either warfarin or aspirin, since the patient had only one major risk factor—hypertension [21, 22]. In 2014, however, updated guidelines now favoured anticoagulation therapy for our patient, despite no change in her risk factors [23, 24].…”

Section: Discussionmentioning

confidence: 99%

Anticoagulation Therapy Considerations in Factor VII Deficiency

Paulus

Komperda

Park

et al. 2016

Drug Saf - Case Rep

View full text Add to dashboard Cite

Factor VII (FVII) deficiency is the most prevalent rare bleeding disorder in the USA and affects approximately 1 out of every 500,000 people. Warfarin inhibits the synthesis of FVII, in addition to other clotting factors. Warfarin is contraindicated in patients with bleeding tendencies or blood dyscrasias; therefore, the literature regarding the use of warfarin in FVII deficiency is very limited. We report a successful re-challenge of warfarin therapy in a patient with FVII deficiency. A 70-year-old woman with FVII deficiency experienced a significant decrease in FVII activity and subsequent vaginal bleeding roughly 5 weeks after starting warfarin for atrial fibrillation. The patient was switched to aspirin therapy. Nearly 4 years later, warfarin therapy was re-attempted by a different haematologist. After 9 months, FVII activity remained in an acceptable range and no bleeding events had occurred. In addition, once the maintenance dose was established, the international normalized ratio remained within the goal range (1.5–2.0) for the majority of assessments. Regarding future considerations, we hypothesize that anticoagulants that do not directly affect FVII, such as the direct oral anticoagulants, would carry less risk of bleeding complications and therefore may be safer alternatives to warfarin to reduce the risk of thromboembolic stroke in patients with atrial fibrillation and FVII deficiency.

show abstract

Section: Discussionmentioning

confidence: 99%

Anticoagulation Therapy Considerations in Factor VII Deficiency

Paulus

Komperda

Park

et al. 2016

Drug Saf - Case Rep

View full text Add to dashboard Cite

show abstract

“…The 2006 guidelines for the treatment of AF 2 recommend flecainide or propafenone for the maintenance of sinus rhythm “in patients with paroxysmal AF who are in sinus rhythm at the time of drug initiation” (Class IIa, Evidence B, page 708). Class IC agents such as fleciainide are now used in approximately 3% of patients with AF, 3 much more often by cardiologists than by internists or family practitioners 4 …”

Section: Discussionmentioning

confidence: 99%

“…To the Editor: The incidence of atrial fibrillation (AF) increases with age 1 . As the population ages, more older adults will seek care for AF, and some will receive drugs such as flecainide 2 . A case of flecainide intoxication in an 87‐year‐old man is reported.…”

mentioning

confidence: 99%

Flecainide Toxicity in an Older Adult

Psaty

2009

J American Geriatrics Society

View full text Add to dashboard Cite

“…All recordings and measurements were performed according to the recommendations of the Committee for M-mode standardization of the American Society of Echocardiography. 7 EF was calculated using the modified biplane Simpson's rule. 8 Left atrial volume was measured at end-systole using biplane area-length method.…”

Section: Transthoracic and Transesophageal Echocardiographymentioning

confidence: 99%